Prior Art Litigation Search in Basel.

A prior art search Basel litigators can build a case on is pharmaceutical and chemical work first, because the patents fought over on the Rhine protect molecules, formulations, second-medical-use claims and dosage regimens rather than gadgets or software. Basel is the headquarters city of Roche and Novartis and the dense pharma, biotech and specialty-chemicals cluster that surrounds them, so the patents asserted here carry some of the largest portfolios in the world. When one of those patents is challenged, the fight runs through the Swiss Federal Patent Court in St. Gallen or through an EPO opposition in Munich, not through the EU’s Unified Patent Court. PerspireIP builds the invalidity and prior-art record those national and European proceedings demand, on the deadlines that govern them.

Why a prior art search Basel case turns on non-patent literature

Every prior art search Basel matter begins with the same question: what kind of claim is this, and what body of literature could actually defeat it? In a city built on pharma and fine chemicals, the asserted claims usually cover a small molecule, a therapeutic antibody, a formulation, a salt or polymorph, a method of treatment or a dosage regimen. The references that invalidate those claims live in journal articles, clinical-trial registries, conference abstracts, regulatory filings and structure-activity literature far more often than in issued patents. A search that only crawls patent databases will miss the art that decides the case.

Chemical and biologic claims also fail for reasons a mechanical or software claim never faces. Lead-compound obviousness turns on whether a skilled chemist would have selected a prior-art compound and modified it with a reasonable expectation of success — both prongs are won on structure-activity and Markush literature the patent itself never cites. Second-medical-use and dosage-regimen claims sit unusually close to the prior art, because earlier trial protocols, published dosing studies and label information can anticipate the very regimen claimed.

That is the discipline PerspireIP brings to every Basel-Stadt matter: exhaustive non-patent-literature retrieval, claim-by-claim mapping, and a written record your litigation counsel can file rather than a raw list of hits they still have to sort.

Litigating validity before the Swiss Federal Patent Court

Patents asserted against a Basel company are litigated before the Swiss Federal Patent Court (Bundespatentgericht / Tribunal fédéral des brevets), a specialised national court with its seat in St. Gallen. Since it began work in 2012, this single court has held exclusive first-instance jurisdiction over the validity and infringement of patents across all of Switzerland, taking over from the 26 cantonal courts that heard patent disputes before it. For a defendant or opponent building an invalidity case, that concentration means the standard of technical scrutiny is high and consistent.

What sets the court apart is its bench. Panels combine legally qualified judges with technically trained judges — chemists, biologists, engineers — who read the prior art the way a person skilled in the art would. A vague reference or an over-argued obviousness theory will not survive that reading. Invalidity arguments have to be anchored in art that genuinely discloses or renders obvious each claim element, with public-availability dates that hold up.

Decisions of the Federal Patent Court can be appealed on points of law to the Federal Supreme Court in Lausanne. Because the technical findings are effectively settled at first instance, the quality of the prior-art record assembled early — before the reply brief, not during it — largely determines the outcome. This is exactly why PerspireIP front-loads searching for Swiss matters.

Switzerland is outside the UPC: why national prior art strategy differs

Switzerland is a member of the European Patent Convention but not of the European Union, and it therefore does not participate in the Unitary Patent or the Unified Patent Court. A European patent granted by the EPO still covers Switzerland, but only through national validation, and once validated it is enforced and challenged in Switzerland alone, before the Swiss Federal Patent Court. The UPC has no jurisdiction here, and a Swiss patent cannot be centrally revoked through it.

That non-UPC status has a direct consequence for a prior art search Basel defendant relies on. A revocation win in the UPC or in a German nullity action does not clear the Swiss designation of the same European patent; that fight has to be run separately in St. Gallen. Conversely, a Swiss defendant cannot piggy-back on a pan-European result and must have its own invalidity record ready for Swiss proceedings.

For a multinational headquartered in Basel, this means invalidity strategy is genuinely multi-forum: national litigation in Switzerland, a possible central EPO opposition, and parallel proceedings in UPC or national courts elsewhere in Europe. We build one consolidated evidence base so the same references can be deployed across every forum, related closely to the wider patent invalidation workstream, rather than commissioning a separate search per country.

EPO opposition: the 9-month central window Basel opponents cannot miss

Even though Switzerland sits outside the UPC, the EPO opposition remains the single most powerful central tool for a Basel opponent. Within nine months of the mention of grant in the European Patent Bulletin, any third party can file an opposition attacking the patent centrally. The deadline is absolute and cannot be extended, so the prior art has to be found and charted before it closes, not afterwards.

The grounds are limited but potent: lack of novelty or inventive step, insufficiency of disclosure, and added subject matter. If the opposition succeeds in revoking or narrowing the claims, that outcome takes effect in every state where the European patent was validated — Switzerland included. A single well-supported opposition can therefore do what dozens of separate national actions would otherwise require.

• Novelty and inventive-step art retrieved against the granted claims, not just the application
• Non-patent literature: journals, clinical-trial registries, conference abstracts and posters
• Insufficiency and added-matter evidence drawn from the prosecution and priority record
• References charted claim-by-claim so counsel can file within the nine-month window

Because opposition and Swiss national litigation draw on the same underlying references, the searching done for one directly strengthens the other. Coordinating the two is where a Basel invalidity campaign is won or lost.

Second-medical-use, dosage regimens and SPCs: where the decisive art lives

Basel pharma litigation rarely turns on the original compound patent, which is usually long expired or unassailable. It turns on the secondary patents that extend a franchise: second-medical-use claims, dosage regimens, formulations, polymorphs and combination products. These claims are close to the prior art by their nature, and the references that defeat them are almost always non-patent literature — earlier trials, dosing studies, review articles and physician practice published before the priority date.

Supplementary protection certificates add another layer. On application by the owner of a Swiss or validated European patent, the Swiss Federal Institute of Intellectual Property can grant an SPC that extends protection for the active ingredient of a medicinal product beyond the base patent term. An SPC is only as strong as the patent behind it, so an invalidity attack on the underlying claim can bring down the certificate as well, and SPC disputes are heard by the same Federal Patent Court.

For an accused generic or biosimilar entrant timing a launch on the Swiss market, this means the prior-art work has to span the whole patent family — base compound, secondary claims and the SPC — because each is a separate barrier to entry and each demands its own body of art.

The non-patent literature that decides Basel pharma cases

The strongest references in a Basel invalidity file are usually the ones a patent-database keyword search never surfaces. Chemical and biologic art is dispersed across specialist journals, structure-activity and Markush literature, clinical-trial registries, regulatory dossiers, conference proceedings and doctoral theses. Each of these can qualify as a prior-art disclosure if it was publicly accessible before the priority date, and each requires a different retrieval method and a verifiable date of public availability.

• Structure-activity and Markush literature for lead-compound obviousness theories
• Clinical-trial registry entries and published protocols for dosage-regimen and method claims
• Conference abstracts, posters and preprints pinned to accessible publication dates
• Regulatory and pharmacovigilance records that predate the priority filing
• Doctoral and institutional theses from Swiss and European university repositories

Retrieving this material takes archive work and subject-matter fluency, not just a database subscription. It is also where a defensive patent infringement analysis and an invalidity search reinforce each other, because the same technical understanding drives both. PerspireIP staffs Basel searches with people who read the chemistry, not only the claims.

How PerspireIP builds a Basel invalidity record

We start from the claims, not the keywords. Each asserted claim is broken into elements, and each element is mapped to the art that reads on it, so a prior art search Basel counsel receives arrives already organised the way an EPO opposition notice or a Swiss nullity brief needs it — not as a raw list of hits.

• Element-by-element claim mapping with anticipation and obviousness charts
• Deep non-patent-literature retrieval: journals, registries, abstracts, theses, dossiers
• Structure-activity and Markush art for chemical lead-compound theories
• Second-medical-use, dosage-regimen and SPC-family coverage across the patent
• Public-availability timelines with verifiable dates for every key reference
• A written invalidity memo grading the strength of each reference, not just its existence

We work as a search partner to your Swiss litigation counsel and European patent attorneys, under confidentiality, to court and opposition deadlines. Whether you are an accused infringer defending in St. Gallen, an opponent racing the nine-month EPO clock, or a generic entrant timing a Swiss launch, the work scales from a single patent to a portfolio-wide campaign and feeds directly into the core prior art litigation search engagement.

We are also candid about what we find. A prior art search Basel defendants commission that turns up weak art is worth knowing early, while settlement, design-around and licensing options are still open and inexpensive. Our invalidity memos grade the references rather than overselling them, because a client betting a launch or an opposition on the strength of that art needs an accurate read, not an encouraging one.

IP Landscape & Resources in Basel

Key intellectual-property authorities and venues relevant to Basel:

• Swiss Federal Institute of Intellectual Property (IPI/IGE) — the Swiss authority that grants national patents and supplementary protection certificates and maintains the register
• Swiss Federal Patent Court (Bundespatentgericht) — the specialised national court in St. Gallen with exclusive jurisdiction over Swiss patent validity and infringement
• European Patent Office (EPO) — grants European patents validated in Switzerland and hears central oppositions within nine months of grant
• Federal Supreme Court of Switzerland — hears appeals on points of law from the Federal Patent Court

Request a Prior Art Search in Basel

Explore related PerspireIP services: Prior Art Litigation Search · Patent Invalidation · Patent Infringement Analysis.

Frequently Asked Questions